An Electrochemical Nucleic Acid Biosensor for Triple-Negative Breast Cancer Biomarker Detection.
Lexi HansenSanket Naresh NagdeveBaviththira SuganthanRamaraja P RamasamyPublished in: Sensors (Basel, Switzerland) (2024)
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, affecting younger women and women of minorities. The nomenclature "triple negative" is derived from the absence of the three most common breast cancer biomarkers: progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). It derives its name from testing negative for these three most common breast cancer biomarkers. Currently, TNBC is diagnosed at advanced stages, necessitating the need for a diagnostic tool or method to identify this malignancy at an early stage prior to metastasis. In this study, a novel electrochemical biosensor was developed, optimized, and evaluated for the detection of microRNA-10b (miRNA-10b), marking the first use of this biomarker for the early diagnosis of TNBC. The biosensor demonstrated the ability to detect concentrations as low as 10 pM. Furthermore, the biosensor was specific toward the target biomarker, distinguishing non-target miRNAs of similar size. The efficacy of the biosensor for TNBC early diagnosis was further validated using human serum samples.
Keyphrases
- label free
- estrogen receptor
- gold nanoparticles
- epidermal growth factor receptor
- early stage
- sensitive detection
- nucleic acid
- breast cancer risk
- polycystic ovary syndrome
- quantum dots
- tyrosine kinase
- endothelial cells
- advanced non small cell lung cancer
- loop mediated isothermal amplification
- pregnancy outcomes
- air pollution
- metabolic syndrome
- radiation therapy
- squamous cell carcinoma
- induced pluripotent stem cells
- cervical cancer screening
- rectal cancer
- molecularly imprinted
- water soluble
- simultaneous determination
- childhood cancer